Thoracic Cancer

Papers
(The H4-Index of Thoracic Cancer is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Issue Information217
Issue Information63
Issue Information54
Issue Information42
Correction to “The Prevalence, Distribution, and Clinicopathological Features of Seven Lung Cancer Actionable Driver Mutations in Taiwan”37
Issue Information35
Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab35
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer34
Adjuvant chemotherapy in node‐positive patients after esophagectomy for esophageal squamous cell carcinoma31
Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report29
Enhancing precision in lung tumor ablation through innovations in CT‐guided technique and angle control29
Comparison of Early Functional Recovery Following Triportal Robot‐Assisted and Uniportal Video‐Assisted Segmentectomy in Patients With Early‐Stage Non‐Small Cell Lung Cancer: A Propensity Score‐Matche28
Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema27
Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer26
Establishing a new human lung squamous cell carcinoma cell line, OMUL‐1, expressing insulin‐like growth factor 1 receptor and programmed cell death ligand 126
Heterogeneity or transformation? A whack‐a‐mole case of EGFR‐mutant lung adenocarcinoma and small cell carcinoma: A case report26
Issue Information24
Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer24
Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report23
Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624‐mediated PD‐L1 pathway23
Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors23
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma23
A case of eosinophilic bronchiolitis after the initiation of immune checkpoint inhibitor22
Thoracic skeletal muscle mass predicts mortality in patients with surgery for pleural empyema: A case control study22
Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation 22
Sortilin‐1, Targeted by miR‐146a, Regulates the Behavior of Non‐Small Cell Lung Cancer22
Multi‐center experience in an optimized right upper lobectomy surgical procedure in China22
PRPS2‐mediated modulation of the antitumor immune response in lung cancer through CCL2‐mediated tumor‐associated macrophages and myeloid‐derived suppressor cells22
0.15405106544495